\begin{table}[ht]
\resizebox{\textwidth}{!}{%
\begin{tabular}{|c|c|c|c|}
\hline
%Drug\_name            & Clinical phase  & Mechanism of Action                                  & Number of  targeted proteins \\ \hline

rug name                & Clinical phase  & Mechanism of Action                                  & \begin{tabular}[c]{@{}c@{}}Number of \\ targeted proteins\end{tabular} \\ \hline


AI-10-49              & Preclinical     & core binding factor inhibitor                        & 52                          \\ \hline
fenebrutinib          & Phase 2         & Bruton's tyrosine kinase (BTK) inhibitor             & 45                          \\ \hline
PF-05190457           & Phase 2         & growth hormone secretagogue receptor inverse agonist & 36                          \\ \hline
abemaciclib           & Launched        & CDK inhibitor                                        & 20                          \\ \hline
MK-5046               & Preclinical     & bombesin receptor agonist                            & 15                          \\ \hline
CFI-402257            & Phase 1/Phase 2 & dual specificity protein kinase inhibitor            & 14                          \\ \hline
CCT137690             & Preclinical     & Aurora kinase inhibitor                              & 7                           \\ \hline
NMS-1286937           & Phase 2         & PLK inhibitor                                        & 5                           \\ \hline
tropifexor            & Phase 2         & FXR agonist                                          & 4                           \\ \hline
NMS-P715              & Preclinical     & protein kinase inhibitor                             & 4                           \\ \hline
cilofexor             & Phase 3         & FXR agonist                                          & 3                           \\ \hline
CDK9-IN-6             & Preclinical     & CDK inhibitor                                        & 3                           \\ \hline
piperaquine-phosphate & Launched        & antimalarial agent                                   & 3                           \\ \hline
elbasvir              & Launched        & HCV inhibitor                                        & 3                           \\ \hline
ABT-702               & Preclinical     & adenosine kinase inhibitor                           & 2                           \\ \hline

adapalene             & Launched        & retinoid receptor agonist                            & 2                           \\ \hline
Q-203                 & Phase 2         & ATP synthase inhibitor                               & 2                           \\ \hline
ziritaxestat          & Phase 3         & autotaxin inhibitor                                  & 2                           \\ \hline
acalabrutinib         & Launched        & Bruton's tyrosine kinase
 (BTK) inhibitor             & 1                           \\ \hline
IACS-10759            & Preclinical     & mitochondrial complex I inhibitor                    & 1                           \\ \hline
CGM097                & Phase 1         & MDM inhibitor                                        & 1                           \\ \hline
\end{tabular}%
}
\caption{Chemicals interacted with human proteins in Tbio} 
    \label{tab:Tbiochemicals}
\end{table}
rug name Clinical phase Mechanism of Action Number of
targeted proteins
AI-10-49 Preclinical core binding factor inhibitor 52
fenebrutinib Phase 2 Bruton’s tyrosine kinase (BTK) inhibitor 45
PF-05190457 Phase 2 growth hormone secretagogue receptor inverse agonist 36
abemaciclib Launched CDK inhibitor 20
MK-5046 Preclinical bombesin receptor agonist 15
CFI-402257 Phase 1/Phase 2 dual specificity protein kinase inhibitor 14
CCT137690 Preclinical Aurora kinase inhibitor 7
NMS-1286937 Phase 2 PLK inhibitor 5
tropifexor Phase 2 FXR agonist 4
NMS-P715 Preclinical protein kinase inhibitor 4
cilofexor Phase 3 FXR agonist 3
CDK9-IN-6 Preclinical CDK inhibitor 3
piperaquine-phosphate Launched antimalarial agent 3
elbasvir Launched HCV inhibitor 3
ABT-702 Preclinical adenosine kinase inhibitor 2
adapalene Launched retinoid receptor agonist 2
Q-203 Phase 2 ATP synthase inhibitor 2
ziritaxestat Phase 3 autotaxin inhibitor 2
acalabrutinib Launched Bruton’s tyrosine kinase (BTK) inhibitor 1
IACS-10759 Preclinical mitochondrial complex I inhibitor 1
CGM097 Phase 1 MDM inhibitor 1